References |
1. Yap DYH, Hai J, Lee PCH, Zhou X, Lee M, Zhang Y, Wang M, Chen X. (2021)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci, 14 (5): 1769-1779. [PMID:33742786] |